Navigation Links
New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility

e of mortality up to 6 months after enrolment.

The primary safety endpoint was major hemorrhagic complications during the same period.

About venous thromboembolism (VTE)

Venous thromboembolism is a general term used to describe the formation of a blood clot (thrombus) that blocks a vein. This may occur in any part of the venous system, but the most common manifestations are deep-vein thrombosis (DVT), usually in the leg, and pulmonary embolism (PE).

VTE is also a common complication among acutely-ill medical patients who have recently been immobilized, a population of medically-ill patients at particularly high-risk for VTE.

About Clexane(R) / Lovenox(R) (enoxaparin)

Lovenox(R) is a unique chemical entity in a class of antithrombotic agents known as low-molecular weight heparin (LMWH). The no. 1 selling low-molecular weight heparin in the world, Lovenox(R) is obtained by alkaline degradation of heparin benzyl ester and is about one-third the molecular size of unfractionated heparin. Lovenox(R) is the most widely studied LMWH, with 20 years of use in the treatment of 185 million patients in 96 countries.

Its clinical applications are linked to its antithrombotic properties. It is used to inhibit clot formation in venous and arterial vessels to prevent potential acute or chronic complications of venous or arterial thrombosis. As with all anticoagulants, the most frequently reported side effect with Lovenox(R) is bleeding. Clinical indications for Lovenox(R) may vary from one country to another.

About sanofi-aventis

Sanofi-aventis is one of the world's leading pharmaceutical companies, ranking number one in Europe. Backed by a world-class R&D organisation, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine and vaccines. Sanofi-aventis is listed in Paris and in New York .


'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
11. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
Post Your Comments:
(Date:10/22/2014)... , Oct. 22, 2014  Rescheduling of hydrocodone ... in the pain market, according to a new ... a firm providing market research and consultation exclusively ... Photo - http://photos.prnewswire.com/prnh/20141021/153440 ... for hydrocodone combination products from Schedule III to ...
(Date:10/22/2014)... Investor-Edge has initiated coverage on the following ... Progenics Pharmaceuticals Inc. (NASDAQ: PGNX ), Threshold ... Inc. (NASDAQ: IDRA ), and Merrimack Pharmaceuticals ... can be accessed at: http://investor-edge.com/register . ... at 4,419.48, up 2.40%, the Dow Jones Industrial Average ...
(Date:10/22/2014)...  Charlene Vernak, RPh, of Vernak Farms Pharmacy in ... awarded the George Roentsch Scholarship by the Professional Compounding ... Houston during PCCA,s International Seminar, ... to an independent pharmacist and PCCA member who embodies ... , a well-known pharmacist in the compounding community. ...
Breaking Medicine Technology:Hydrocodone: Rescheduled, Repositioned & Reinvented 2Hydrocodone: Rescheduled, Repositioned & Reinvented 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 2Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 4Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 5PCCA Awards Charlene Vernak, RPh, the George Roentsch Scholarship 2
... LA JOLLA, Calif., Sept. 27, 2011 The Wireless-Life ... Wireless Health 2011, where researchers from global institutions such ... universities will share the best new research and significant ... academia, medicine, government and industry. The ...
... Masimo (NASDAQ: ... new study published in the Journal of Critical ... (SpHb®) monitoring has absolute and trending accuracy similar to ... advantages.  Study highlights that "the ability to measure hemoglobin ...
Cached Medicine Technology:Aging-in-Place Research Breakthroughs To Be Presented At Wireless Health 2011 Conference 2Aging-in-Place Research Breakthroughs To Be Presented At Wireless Health 2011 Conference 3Published Study Demonstrates the Absolute and Trend Accuracy of Masimo Noninvasive and Continuous Total Hemoglobin (SpHb) Monitoring in Intensive Care Unit Patients 2Published Study Demonstrates the Absolute and Trend Accuracy of Masimo Noninvasive and Continuous Total Hemoglobin (SpHb) Monitoring in Intensive Care Unit Patients 3Published Study Demonstrates the Absolute and Trend Accuracy of Masimo Noninvasive and Continuous Total Hemoglobin (SpHb) Monitoring in Intensive Care Unit Patients 4Published Study Demonstrates the Absolute and Trend Accuracy of Masimo Noninvasive and Continuous Total Hemoglobin (SpHb) Monitoring in Intensive Care Unit Patients 5Published Study Demonstrates the Absolute and Trend Accuracy of Masimo Noninvasive and Continuous Total Hemoglobin (SpHb) Monitoring in Intensive Care Unit Patients 6
(Date:10/25/2014)... CA (PRWEB) October 25, 2014 More ... annual President’s Circle Reception on Monday at the home ... accomplishments and hear from guest speaker Dr. Winifred Lender ... worlds. , Dr. Lender, a Santa Barbara psychologist, author ... challenges and benefits of living in the digital age. ...
(Date:10/25/2014)... QueenBeeTickets.com has a variety of tickets for online ... Bob Seger & The Silver Bullet Band tickets for ... going on sale October 25 and are expected to ... the selection of tickets for Bob Seger & The ... is touring North America beginning next month, and he ...
(Date:10/25/2014)... Oct. 24, 2014 (HealthDay News) -- Interrupting blood supply to ... reduce the risks associated with the surgery, according to a ... stop the blood supply to the heart to be able ... the heart will reduce its ability to produce energy because ... flow to another large muscle, such as an arm or ...
(Date:10/25/2014)... Current osteoporosis screening guidelines and tools fail to ... osteoporosis-related fractures, a new study says. "If ... that help us accurately predict who will suffer ... these at-risk people for preventive measures," study author ... division of general internal medicine and health services ...
(Date:10/22/2014)... October 22, 2014 On October 22, ... featuring skin diseases both fictional and real. The ... a nonprofit organization committed to advocacy and philanthropy in ... will take the opportunity to impart truth and clarity ... , There are many misconceptions about Morgellons Disease ...
Breaking Medicine News(10 mins):Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 2Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 3Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 4Health News:QueenBeeTickets.com Features Bob Seger & The Silver Bullet Band Tickets for Charleston Civic Center, Huntington Center, and Nationwide Arena at Reduced Prices 2Health News:Brief Interruption of Blood Supply to Limb Might Aid Heart Surgery: Study 2Health News:Osteoporosis Screening Guidelines May Miss Younger Women at Risk 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3
... clinical trials on a new investigational drug being developed ... been successfully completed. Completion of the initial phase ... prepared by researchers at Cardiff University,s Welsh School of ... an approved medicine have significantly improved. Approximately ...
... N.C. Millions of patients with advanced disease in palliative ... easily. But a new study from Duke University Medical ... intervention, and among those who do benefit, it doesn,t make ... just plain old room air both offer equal benefit. ...
... Reporter , THURSDAY, Sept. 2 (HealthDay News) -- An ... two hours, making only one doctor visit necessary before ... advance against a disease that kills nearly 2 million ... "This is a very important discovery," said infectious disease ...
... and a little serendipity led a Northwestern University research team ... used for gas storage and food and medical technologies. And ... first known all-natural metal-organic frameworks (MOFs) that are simple to ... the Northwestern MOFs you can pop into your mouth and ...
... Stem cells might be thought of as trunks in the ... can turn into a dazzling variety other cellskidney, brain, heart ... the capacity to turn into virtually any cell type in ... of cell therapies, the conquering of age-old diseases or even ...
... September, 2010 - Elsevier announced today the publication of ... Andropause Society (EMAS) in the journal Maturitas ... post-reproductive health of women. The statements cover the ... epilepsy, endometriosis and premature ovarian failure. Each statement ...
Cached Medicine News:Health News:First clinical trials successfully completed on potent new hepatitis C drug 2Health News:Study challenges value of oxygen therapy in end-of-life care 2Health News:Study challenges value of oxygen therapy in end-of-life care 3Health News:Experimental TB Test Called Fast and Accurate 2Health News:Experimental TB Test Called Fast and Accurate 3Health News:Edible nanostructures 2Health News:Edible nanostructures 3Health News:Study finds that cancer-causing gene crucial in stem cell development 2Health News:Study finds that cancer-causing gene crucial in stem cell development 3Health News:EMAS publishes position statements about the post-reproductive health of women 2
1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride, 7.5% Glycerol....
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
Inoculum Broth with Calcium Chloride and Phytone....
12% Tryptone, 24% Yeast Extract, 4.0% Glycerol. Supplied with 1 liter of 10x phosphate buffer (0190-1L)....
Medicine Products: